News & Publications

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

April 9, 2024

Deep breaths, deep dives: The new eFlow Integrated nebuliser

Published

November 29, 2023

Category

Publications

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

Published

November 8, 2023

Category

Publications

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.

Published

November 3, 2023

Category

Publications

Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.

Published

October 2, 2023

Category

Publications

Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

News, Publications & Insights

In the Spotlight

Partner Project News

PARI Publication

Deep breaths, deep dives: The new eFlow Integrated nebuliser

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.

Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.

Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.

Contact us

PARI Business Development Team